Randomised trials of ICDs for primary and secondary prevention of SCD in patients with heart failure
Name of trial | Heart failure aetiology and severity | Number of patients | Additional risk stratification tool | Treatment groups | Primary and *secondary outcomes | Result |
---|---|---|---|---|---|---|
CABG, coronary artery bypass graft; CRT, cardiac resynchronisation therapy; DCM, idiopathic dilated cardiomyopathy; EPS, electrophysiological study; ICD, implantable cardioverter-defibrillator; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NS, non-significant; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; PVC, premature ventricular complex; QOL, quality of life; SAECG, signal averaged ECG; VF, ventricular fibrillation; VT, ventricular tachycardia. | ||||||
AVID29 | Mean LVEF 32% | 1016 | Resuscitated VF or VT | 1. Class III antiarrhythmic drugs | 1. Total mortality | 1.39% relative risk reduction |
2. ICD | *2. QOL | |||||
*3. Cost | ||||||
CIDS30 | Mean LVEF 34% | 659 | Resuscitated VF or VT or unmonitored syncope | 1. Amiodarone | 1. Total mortality | 1.20% relative risk reduction (NS) |
2. ICD | *2. Arrhythmic death | 2.33% relative risk reduction (NS) | ||||
MADIT17 | Previous MI, NYHA I–III, LVEF <35% | 196 | Asymptomatic NSVT with inducible sustained VT at EPS | 1. Medical treatment | 1. Total mortality | 1.54% relative risk reduction |
2. ICD | ||||||
MUSTT18 | IHD, LVEF <40% | 704 | Asymptomatic NSVT with inducible sustained VT at EPS | 1. Antiarrhythmics and ICD | 1. Cardiac arrest or death from arrhythmia | 1.27% relative risk reduction |
2. No antiarrhythmic treatment | *2. Total mortality | 2.20% relative risk reduction | ||||
*3. Sustained VT | 3. NS | |||||
CABG-Patch14 | CABG surgery, LVEF <36% | 900 | Abnormal SAECG | 1. ICD | 1. Total mortality | 1. NS |
2. Control | ||||||
MADIT II4 | Prior MI, LVEF <30% | 1232 | None | 1. Medical treatment | 1. Total mortality | 1. 31% relative risk reduction |
2. ICD | ||||||
SCD-HeFT9 | IHD or DCM, NYHA II–III, LVEF <35% | >2500 | None | 1. Amiodarone | 1. Total mortality | 1. Amiodarone v placebo: No reduction. ICD v placebo: 23% relative risk reduction |
2. Placebo | ||||||
3. ICD | ||||||
AMIOVIRT31 | DCM, NYHA I–III, LVEF <35% | 103 | Asymptomatic NSVT | 1. Amiodarone | 1. Total mortality | 1. NS |
2. ICD | *2. Arrhythmia-free survival | 2. NS | ||||
*3. QOL | 3. NS | |||||
*4. Cost | 4. NS | |||||
CAT7 | DCM <9 months, NYHA II–III, LVEF <30% | 104 | None | 1. Control | 1. Total mortality | 1. NS |
2. ICD | ||||||
DEFINITE12 | DCM, LVEF <36% | 458 | PVCs or NSVT | 1. Medical treatment | 1. Total mortality | 1. 35% relative risk reduction (NS) |
2. Medical treatment + ICD | 2. Arrhythmic death | 2. 80% relative risk reduction | ||||
COMPANION8 | IHD or DCM, NYHA III–IV, LVEF <35% | 1520 | None | 1. Control 2. CRT | 1. Death from or hospitalisation for any cause | CRT ICD v control 1. 19% relative risk reduction |
3. CRT with ICD | *2. Death or hospitalisation from heart failure | 2. 40% relative risk reduction | ||||
*3. Total mortality | 3. 36% relative risk reduction |